Cultivators Rely on Superior Cannabis Products to Gain Market Share

Cannabis legalization has spread around the world as, according to a study conducted by Columbia University’s Mailman School of Public Health, the number of users has exponentially risen between 2007 and 2014. 2014 was the year that Colorado and Washington made headlines after becoming the first two U.S. states to legalize recreational cannabis. Before the states’ decision that year, only medical use was sanctioned in the few regions where cannabis had a presence. However, by the time the study took place in 2017, there were already 29 states and the District of Columbia that legalized medical cannabis and 8 states that legalized recreational use. The study discovered that adults between the ages of 26 and 34 witnessed a 4.5% increase in cannabis consumption and that daily cannabis use was primarily higher among adults between the ages of 18 and 34. Pia M. Mauro, PhD, Assistant Professor of Epidemiology at the Mailman School of Public Health, noted that the increase in daily and nondaily usage among adults was predominantly due to legalization efforts, attitudes and risk perception. Currently, most people consuming cannabis use it for medicinal purposes. However, industry experts believe that as legalization continues to sweep throughout the U.S., the recreational market will eclipse its medical counterpart. Now, more and more people are willing to try cannabis if it becomes legalized. Moreover, as the cannabis industry continues to grow, retailers are working to introduce new and innovative products to their consumers. Now, producers have created cannabis-based products that appeal to both spectrums of users, whether they are frequent or infrequent users. Nonetheless, with the combination of the medical market and frequent recreational users, potent marijuana strains are expected to remain on top of the market demand. According to data compiled by Verified Market Research, the global marijuana market was valued at USD 42.20 Billion in 2016. By 2025, the market is expected to reach USD 466.81 Billion while registering a CAGR of 35.3% from 2018 to 2025. Cannabix Technologies Inc. (OTC: BLOZF), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Origin House (OTC: ORHOF) (CSE: OH), Harvest Health & Recreation Inc. (OTC: HRVSF) (CSE: HARV)

U.S. CBD Hemp Product Revenues Predicted to Surge Over the Next Few Years

There is a lot of anticipation and optimism surrounding the medical and recreational marijuana markets revenues but the hemp/CBD market should not be ignored. A recent report from a respected industry source, BDS Analytics says that the collective market for CBD sales is expected to exceed $20 billion in the United States by 2024. This pretty much supports the reports from another industry respected source, The Brightfield Group, which has previously projected that the: “Hemp CBD Market to Reach $22 Billion By 2022: Outpacing the Rest of the Cannabis Market Combined”. It is important to understand that CBD is derived from both marijuana and hemp. One industry publication describes the difference as follows: “It is the distinction between CBD derived from marijuana and CBD from hemp oil that sets them apart. Marijuana is harvested for its buds, which contains psychoactive properties known to produce stoned effects. When it comes to hemp, the stalks and seed are the targets of this crop. These plants do not contain enough THC to get anyone high. In fact, for cannabis to be considered hemp, it must have no more than 0.3 percent THC. Just think of hemp oil-based CBD as a vitamin (high in Potassium and Magnesium) and the bud-based products to be pharmaceutical grade.” Active Companies in the market this week include: MYM Nutraceuticals Inc., (CSE: MYM) (OTCQB: MYMMF), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Curaleaf Holdings, Inc. (CSE: CURL) (OTCQX: CURLF), Village Farms International, Inc. (NASDAQ: VFF) (TSX: VFF), CV Sciences, Inc. (OTCQB: CVSI).

Data Points to Cannabis Emergence as a Viable Part of Cancer Treatment

The burden of symptoms associated with medical conditions has ravaged millions of people around the globe. Every day, people suffering from medical conditions are distraught by the harsh effects of the symptoms derived from their ailments. For instance, patients receiving cancer therapy can face a plethora of side effects such as nausea and severe pain. Generally, patients may take other medicines in order to subdue these side effects, and in particular, cancer patients suffering from chronic pain may be prescribed opioids from their physician. The major downside of these treatments is that opioids have life-threatening consequences. Overall, cancer patients suffer from side effects associated with cancer therapies as well as the treatments used to control their side effects. As a result, more medical institutions are beginning to recommend cannabis as an alternative to treat the adverse associated with cancer. The American Cancer Society has cited studies that determined that marijuana can be helpful in treating the side effects of cancer chemotherapy. A few studies have even uncovered that inhaled (smoked or vaporized) marijuana can help with the treatment of neuropathic pain. And more recently, scientists have also reported that THC and other cannabinoids such as CBD can slow the growth of and possibly eliminate cancer cells, ultimately reducing the spread of certain forms of cancer. Other studies have suggested that cannabinoids can be safe for humans in treating cancer, which has led to the wide spread of medical cannabis around the world. As more global government agencies collect positive data from clinical trials, more countries will move towards legalizing medical cannabis because of its valuable therapeutic effects. And as a result, the global legal marijuana market is expected to reach USD 146.4 Billion by 2025 while registering a CAGR of 34.6%, according to data compiled by Grand View Research. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), HEXO Corp. (NYSE: HEXO) (TSX: HEXO).

Latest Reports Project Continued Steady Growth for Canadian Cannabis Market

Projections for the Canadian cannabis markets (medical & recreational) are numerous and vary… but the one thing they all agree on is that the markets will continue to rise… substantially! In a report, Cannabis Business Plans describes the overall picture as follows: “Canadian cannabis market has been steadily growing. The country has seen an average of a 10 percent increase each month in the number of Canadian patients signed up to receive medical cannabis. The sale of dried cannabis has grown steadily at 6 percent a month, and the sale of cannabis oil has been growing by 16 percent a month. In 2017, about 4.9 million Canadians aged 15 to 64 spent an estimated $5.7 billion on cannabis for medical and non-medical purposes. This was equivalent to around $1,200 per cannabis consumer. In 2018, Canadians spent $1.6 billion on legal cannabis, more than double the amount that was spent on solely medical cannabis in 2017, according to a new report “The State of Legal Marijuana Market”, released by Arcview Market Research and BDS Analytics. Active companies in the industry making moves to ready that include: Choom(TM) Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Fire & Flower Holdings Corp. (TSX-V: FAF) (OTCPK: FFLWF), National Access Cannabis Corp. (TSX-V: META) (OTCPK: NACNF), Tilray, Inc. (NASDAQ: TLRY).